#United States #New York #Class Action #Securities Fraud #UroGen Pharma

UroGen Pharma Investors Urged to Join Class Action Lawsuit

Levi & Korsinsky, LLP has reached out to investors of UroGen Pharma Ltd. regarding a significant class action securities lawsuit. This legal action aims to represent shareholders adversely impacted due to alleged securities fraud occurring between July 27, 2023, and May 15, 2025.

Background of the Case

UroGen Pharma, a biotechnology company focusing on developing innovative solutions for urological conditions, faces scrutiny amid allegations that it misled investors about its clinical trials and drug efficacy. The lawsuit specifically outlines five major claims against the company:

1. Misleading Clinical Study Design: It is alleged that UroGen’s ENVISION clinical study did not properly demonstrate the effectiveness of UGN-102, its leading pipeline product, due to a lack of a concurrent control arm. This design flaw potentially hampered the ability to prove the drug's efficacy convincingly.

2. Failure to Acknowledge FDA Warnings: The lawsuit claims the company ignored specific warnings from the FDA regarding the clinical study’s design, which could ultimately affect the approval of UGN-102.

3. Investment Risks and Misleading Statements: The action contends that UroGen's positive statements regarding its products and future prospects lacked a reasonable basis, putting investors at risk of significant losses.

The lawsuit seeks to recover financial losses for UroGen investors who bought shares during the defined period. Investors are encouraged to act quickly, as the deadline for requesting to be appointed as lead plaintiff is July 28, 2025.

Class Action Participation

For investors who suffered losses, becoming part of this class action can provide a pathway to potential compensation without incurring out-of-pocket costs. The process holds that if the court rules in favor of the investors, they could receive a portion of the recoveries without the obligation to fund the lawsuit directly.

Levi & Korsinsky boasts a successful track record in securities litigation, having secured hundreds of millions of dollars for aggrieved shareholders over the past two decades. Their team emphasizes that participation in this class action involves no cost to shareholders and is a crucial step in protecting their financial interests.

How to Get Involved

Affected investors can learn more and ensure their rights are represented by submitting a contact form available through this link. Investors may also contact Joseph E. Levi, Esq., directly at his office at Levi & Korsinsky or by calling (212) 363-7500.

As the situation develops, shareholders are advised to keep abreast of communications from UroGen Pharma and Levi & Korsinsky to ensure they don’t miss important updates regarding this case.

Conclusion

The emergence of this class action presents a crucial opportunity for individuals affected by the alleged deceptive practices of UroGen Pharma. All impacted investors should consider participating to safeguard their interests as the legal proceedings unfold. Only through collective action can affected shareholders move towards recovery and accountability for their losses.